Yahoo Finance

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL ...

CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced positive initial safety and efficacy data from the ...
Yahoo Finance

Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and ...